We highly recommend Opcon-A Allergy Eye Drops by Bausch + Lomb to anyone experiencing red, itchy, and irritated eyes due to allergies. Opcon-A Allergy Eye Drops are a great solution for anyone who ...

Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...